

Product Data Sheet

Ralfinamide mesylate

Cat. No.: HY-101437A
CAS No.: 202825-45-4
Molecular Formula: $C_{18}H_{23}FN_2O_5S$

Molecular Weight: 398.45

Target: Sodium Channel

Pathway: Membrane Transporter/Ion Channel

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	Ralfinamide mesylate (FCE-26742A mesylate) is an orally available Na $^+$ channel blocker derived from α -aminoamide, with function of suppressing pain ^{[1][2]} .	
IC ₅₀ & Target	$Na^{+}channel^{[1]}$	
In Vivo	Ralfinamide (30 mg/kg, 60 mg/kg; p.o.; twice daily; 42 days) treated with Ralfinamide (80 mg/kg; p.o.; twice daily; 7 days) preoperatively suppresses neuropathic pain ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	81 adult male Sprague–Dawley male rats (260–460 g) ^[1]
	Dosage:	80 mg/kg (7 days preoperatively), 30 mg/kg, 60 mg/kg (postoperative)
	Administration:	Oral gavage; twice daily; until postoperative day 42
	Result:	Suppressed neuropathic pain.

CUSTOMER VALIDATION

• Acta Pharmacol Sin. 2021 Jun 8.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Zhang SH, et al. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain. 2008 Oct 15;139(2):293-305.

 $[2]. \ Liang X, et al. \ Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain. Eur J Pharmacol. 2018 \ Mar 15;823:27-34.$

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com